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We wanted to ascertain whether the current format of lipid laboratory reports seemed adequate to promote identification and treatment of patients with dyslipidemia. In a random survey of lipid laboratory reports from 25 laboratories, we found great inconsistencies among reporting formats and contents. Fewer than half the laboratories correctly reported the ranges for cholesterol, only 4 correctly reported ranges for high-density lipoprotein cholesterol, only 2 correctly reported ranges for triglycerides, and none presented low-density lipoprotein cholesterol ranges in terms of risk factors for coronary heart disease. Reports typically were disjointed and difficult to read. The current practice of reporting results for lipid panels is confusing and does not follow the National Cholesterol Education Program (NCEP) guidelines. We recommend that reporting of results be standardized, and a "model" standardized report is presented herein, based on consensus from a team of experts. The standardized report uses current recommendations for ranges, follows the flowcharts of the NCEP guidelines, and takes the patient's clinical condition (the number of risk factors and the presence of coronary heart disease) into consideration. Standardizing lipid reports should decrease confusion and perhaps increase application of the guidelines and patient compliance with treatment.
In the United States, coronary heart disease is still the leading cause of mortality, accounting for almost one-half million deaths per year (1 of 5 deaths). 1 Since 1995, more than 1 million Americans have experienced a coronary event, approximately half of them new, and in about one third of cases the patients have died. 1 About 12 million Americans currently have a history of coronary heart disease, as evidenced by angina, myocardial infarction, or both. At present, coronary heart disease is the leading cause of premature or permanent disability in the United States, accounting for 19% of the disability allowances by the Social Security Administration. Since the induction of the National Cholesterol Education Program (NCEP; 1986 to 1996), the death rate from coronary heart disease has declined 27%, while the total number of deaths from all causes has declined only 8.6%. While these results are encouraging, organized medicine can achieve more success in the secondary and primary prevention of myocardial morbidity resulting from coronary heart disease.
The curtailment of smoking, enactment of physical activity, reduction of obesity, and management of hypertension, diabetes mellitus, and dyslipidemia will reduce the consequences of coronary heart disease. The process of optimizing lipid concentrations begins with the patient-physician relationship but requires the biochemical determinations of total cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides, and low-density lipoprotein (LDL)-cholesterol. The clinical chemistry laboratory must ensure that the specimen is collected properly, that the lipids are analyzed properly, and that the results are reported so that the physician can interpret them easily and readily and the patient can understand their implications.
The NCEP has recommended analytic performance guidelines to laboratories for lipid measurements. 2, 3 Initially, 81% of laboratories met these guidelines for cholesterol, and 61% of laboratories met them for HDL-cholesterol. 4 Watson et al 5 have shown improvement in the measurement of cholesterol, with 100% of 19 laboratories under study meeting the accuracy guidelines for cholesterol concentrations at 200 and 240 mg/dL (5.18 and 6.22 mmol/L). 5 Laboratories using the new direct LDL-cholesterol method demonstrated excellent accuracy, meeting the performance criteria of the Centers for Disease Control Lipid Standardization Program. 6 To aid clinical laboratories, the Centers for Disease Control and Prevention established a network of reference laboratories to provide materials for verification of the standardization of lipids and lipoproteins. 7 Despite the efforts of the NCEP and the improvements in the preanalytic and analytic phases of clinical laboratory testing, the outcomes in controlling blood lipids and decreasing coronary heart disease have not met expectations. In a group of 95 patients referred to cardiologists for coronary angiography, only 21% eligible for treatment received any form of treatment, while 33% of this group had not undergone testing of their lipids status. 8 This latter group of patients, when tested for lipids, had a mean cholesterol concentration of 242 mg/dL (6.27 mmol/L), implying that lipid screening would have identified a large fraction of them as being at risk. 8 Of the patients in the study (having a mean cholesterol concentration of 255 mg/dL [6.60 mmol/L] and mean LDL-cholesterol concentration of 172 mg/dL [4.45 mmol/L]), 31% had been told they had a lipid abnormality but had not received treatment. 8 A study of data from the Behavioral Risk Factor Surveillance System revealed that 39.6% of 126,571 persons seen by a physician during the previous 2 years for preventive care had not been screened for high blood cholesterol concentration. 9 In a study of 15,800 persons in 4 communities in the United States, 84% of subjects with hypertension were aware of their condition, and 50% were treated successfully, whereas only 42% of subjects with hypercholesterolemia were aware of their condition, and only 4% were treated and hypercholesterolemia controlled successfully. 10 Fewer than 20% to 30% of patients with coronary heart disease receive adequate cholesterol-lowering therapy in academic centers; in more general practice, only 14% of patients with coronary heart disease had their LDL-cholesterol treated adequately to goal. 11 The great number of patients with demonstrated coronary heart disease who have not been tested or treated for dyslipidemia or treated to the recommended goal of 100 mg/dL (2.59 mmol/L) of LDL-cholesterol indicates that primary care physicians do not consistently follow the recommendations of the second NCEP Adult Treatment Panel II. 11 McBride et al 11 stress that the medical community must overcome the barriers to successful management of cholesterol disorders, emphasizing that primary care physicians must develop strategies to test and treat all eligible patients. We assessed the level of involvement in lipid testing by the clinical laboratory and noted that current report formats for lipid values seemed inadequate to easily communicate the clinical relevance of these measurements to the clinician. This study presents a survey of the current status of lipid panel reports and suggests improvements by standardizing the information and appearance of those reports. Members of the Lipids and Lipoprotein Division of the American Association for Clinical Chemistry prompted this study because they had made similar observations, though not by means of a formal process.
Methods
We took a random survey of lipid panel reports from 25 laboratories around the United States. Laboratories were selected to yield a cross-section of types of laboratories. Twenty-five laboratories responded: 10 from regional offices of national reference laboratories, 9 from local reference or community hospital laboratories, 5 from hospital laboratories associated with academic institutions, and 1 from a health maintenance organization. We assessed how well the laboratories reported results according to NCEP guidelines, paying particular attention to consistency of numeric reference ranges, linguistic terminology, clinical usefulness, and readability.
Results
The numeric reference ranges for the reviewed reports are presented, in random order, in ❚Table 1❚. Ten laboratories reported cholesterol concentrations correctly in terms of desirable, borderline-high, and high risk for the development of coronary heart disease; however, 3 of these laboratories (Q, U, and W) augment the values with an interval in addition to the risk-oriented ranges. The remaining laboratories present single reference intervals, such as 0-199, 100-200, 100-240, 120-220, 125-210, and 144-269 (all in mg/dL; to convert to millimoles per liter, multiply by 0.0259).
Only 4 laboratories correctly reported the desirable HDL-cholesterol reference range as 35 mg/dL (0.91 mmol/L) or more. The rest of the laboratories reported ranges with the lowest value around 35 mg/dL (0.91 mmol/L), but 2 laboratories indicated the range for male and female subjects. Some laboratories attempted to classify HDL-cholesterol in terms of borderline and high risk, while some laboratories (L and M) presented reference intervals that are not supported by current literature. Only Nine laboratories presented the LDL-cholesterol reference ranges in terms of desirable, borderline-high, and high risk; 5 presented the reference range in terms of less than 130 mg/dL (3.37 mmol/L), alone; while the rest of the laboratories presented various ranges. No laboratory stratified ranges for LDL-cholesterol according to risk factors or the presence of coronary heart disease. Three laboratories presented the cholesterol/HDL-cholesterol ratio of less than 5.0 as desirable; 2 laboratories gave results for the ratio but failed to provide a reference interval; 2 laboratories gave alternative reference intervals; the rest of the laboratories did not report the ratio. (The NCEP does not recommend use of the ratio, but we present it because many physicians find it useful.) We observed readability problems with the reports in addition to the problem with the ranges. Many reports present the results and ranges in a disjointed fashion with the lipid values printed on 2 or more pages. No laboratory reported or acknowledged risk factors. Notes frequently intervened between laboratory values. In some cases, LDLcholesterol was not reported when triglycerides exceeded 400 mg/dL (4.51 mmol/L). The order of reporting lipids (eg, cholesterol, triglycerides) varied from report to report and often failed to follow a logical sequence.
Discussion
The huge variation in reference ranges, order of reporting, disjointed placement of test results, and failure to list risk factors can only cause confusion. To improve their clinical usefulness, we recommend lipid reports be standardized. We suggest placing the NCEP guidelines at the head of the report, with an assessment of clinical risk factors. Placement of the clinical risk factors at the head of the report will aid physicians to calculate the number of risk factors and categorize their patients, so that they can use the appropriate reference range for LDL-cholesterol. In ❚Figure 1❚, we present our suggested version of a standardized report format.
The standardized laboratory report contains many important features that correct earlier-mentioned deficiencies. The report pools all of the results in one area, improving readability. Instead of using a reference range, the report states desirable levels for the 4 tests and 1 ratio. The desirable level for LDL-cholesterol includes 2 levels: less than 130 mg/dL (<3.37 mmol/L) for patients without coronary heart disease (primary prevention) and less than 100 mg/dL (2.59 mmol/L) for patients with evidence of coronary heart disease (secondary prevention). Under comments, the report includes the LDL-cholesterol goals for therapy; these goals are stratified by the presence or absence of coronary heart disease and by the number of risk factors. Because risk factors have a pivotal role in interpreting LDL-cholesterol levels and the classification scheme of the Adult Treatment Panel II, we positioned them at the head of the report. The table for the risk factors includes a scoring system, 1 point added for each positive risk factor and 1 point subtracted for an HDL-cholesterol concentration of 60 mg/dL (1.55 mmol/L) or more (the negative risk factor). Thus, a physician scanning down the report would have the number of risk factors available by the time he or she reached the LDL-cholesterol values. We added an additional note that a full lipid panel should be performed, if not already requested, whenever the cholesterol concentration is more than 240 mg/dL (6.22 mmol/L) or between 200 and 239 mg/dL (5.18 and 6.19 mmol/L) with 2 or more risk factors, the HDL-cholesterol concentration, is less than 35 mg/dL (0.90 mmol/L) irrespective of the cholesterol concentration), or the patient has coronary heart disease or clinical peripheral vascular disease.
The report in this format follows the cut-points of the Adult Treatment Panel II and should lead the clinician through the proper pathways. In addition, because the report will be consolidated onto 1 sheet of paper, the clinician has the opportunity to share the contents with the patient, emphasizing the pertinent clinical and laboratory findings. The clinician can give a copy of the report to the patient to further motivate compliance with therapy. Because many laboratories transmit their results through computers, we have set the example report (Figure 1 ) in Courier typeface, which has a constant space for each character, a typeface that will work with all computer systems. With more advanced laboratory information systems, one could use a more modern typeface to produce a more aesthetically pleasing report.
Clinicians can manage the majority of lipid disorders with the measurement of cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol calculated by the Friedewald formula. 12 Clinical laboratories have continued to improve methods for lipid testing. HDL-cholesterol has been measured for more than 30 years using a 2-step method, separation and centrifugation, which is tedious and inefficient. 13 A new class of fully automated "homogeneous" methods was introduced that demonstrate reasonable accuracy and improved precision. [14] [15] [16] [17] [18] [19] Some of the new methods may give discrepant results on specimens from patients with type III dyslipidemia or with renal or hepatic disease. 20, 21 When type III dyslipidemia is suspected, one should use ultracentrifuged samples to determine the VLDL (very-lowdensity lipoprotein) cholesterol/triglycerides ratio and refer such patients to a medical or academic center specializing in lipid disorders. 12 Most laboratories calculate LDL-cholesterol using the Friedewald formula. This formula agrees (within ± 10%) with the beta-quantification method 90% of the time for concentrations of triglycerides less than 200 mg/dL (2.26 mmol/L), 72% of the time with concentrations of triglycerides of 200 to 400 mg/dL (2.26-4.52 mmol/L), and 39% of the time with concentrations of triglycerides of 400 to 600 mg/dL (4.52-6.78 mmol/L). 22 Other studies have shown better results with the Friedewald formula. 23 Fully automated homogeneous LDL-cholesterol methods have been marketed and show good precision and agreement with beta-quantification but await further studies before use on a routine basis. [24] [25] [26] [27] [28] [29] Their use is indicated when the concentration of triglycerides is more than 400 mg/dL (4.52 mmol/L).
Practice of the guidelines in the Adult Treatment Panel II can effectively decrease morbidity and mortality due to coronary heart disease. In the Scandinavian Simvastatin Survival Study, treatment with simvastatin reduced mortality from 12% (control group) to 8% (treatment group). 30 In the West of Scotland Coronary Prevention Group study, administration of pravastatin to men with hypercholesterolemia but without coronary heart disease (primary prevention) reduced the incidence of myocardial infarction by 31% and cardiac death by 32%. 31 In patients with coronary heart disease with borderline cholesterol values (200-239 mg/dL [5.18-6.19 mmol/L]), treatment with pravastatin reduced fatal and nonfatal myocardial infarction by 3.3%. 32 Aggressive reduction of LDL-cholesterol concentration delays progression of atherosclerosis in saphenous vein grafts by 31%, improves the quality and the length of life in elderly people, and improves diminished myocardial vasodilatation in patients with hypercholesterolemia. [33] [34] [35] Reduction of LDL-cholesterol with atorvastatin is as least as effective as angioplasty in reducing ischemic events. 36 Treatment with gemfibrozil in patients with coronary heart disease reduced the incidence of major cardiovascular events by 22%. 37 Treating coronary heart disease patients with simvastatin has decreased per-patient hospitalization costs by 31%, and secondary prevention has proved cost-effective for the 40-to 70-year age group. 38, 39 Recent outcome studies with statin drugs show their use in secondary and primary prevention would cost less than $50,000/year-life-saved. 40 Even though the treatment of lipid disorders is clinically and economically effective, the previously mentioned studies show that few patients are treated for their lipid disorders and that fewer are treated to the therapeutic goal. Failures to treat are missed opportunities, and we must improve risk assessment. 41, 42 Failure to treat occurs not because of a paucity of professional recommendations but because of inadequate recording of risk factors. 41 Laboratory reports that include inaccurate reference ranges and disjointed grouping of analyte values and ignore risk factors fail to communicate, hinder risk assessment, and hamper implementation of treatment. Correcting the deficiencies of the lipid panel laboratory report provides an opportunity to improve communication and recording of risk factors, with the hope of reducing morbidity and mortality due to coronary heart disease.
In the near future, the clinical laboratory will need to critically examine the validity of assaying evolving risk factors, such as C-reactive protein, homocysteine, lipoprotein(a), fibrinogen, inflammatory and oxidative stress markers, and markers of cardiovascular dysmetabolic syndrome. When these new markers are believed to add value to the assessment of coronary heart disease and atherosclerosis, the clinical laboratory should add them to the suggested report format. Also, in the future a patient's risk assessment, based on the Framingham model, might be provided to select patients for therapy in primary prevention. 43 
